Observational cohort for systemic lupus erythematosus in Saudi Arabia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort aims to define systemic lupus erythematosus (SLE) in Saudi Arabia, a region with unique genetic factors due to high consanguinity. The study will follow an open cohort design to gather comprehensive data on disease presentation, progression, and outcomes. By collecting detailed immunological, molecular, genetic, and microbiome information, the study seeks to address the gaps in understanding SLE in this population, which has been primarily based on retrospective analyses. This prospective approach is expected to yield more reliable and relevant data for SLE management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adult patients defined as age greater than 18 years old.
2. Patients should fulfil one of the following classification criteria for SLE (ACR, SLICC or ACR/EULAR criteria).
3. No restriction on time of diagnosis.

Exclusion Criteria:

* Patients who don't fulfil classification criteria mentioned above.

Where it's running

• king Saud University medical city
  Riyadh, Central Province, Saudi Arabia Recruiting

Study contacts

• Study coordinator: Ibrahim Almaghlouth, MSc(c), AmBIM, FRCPC, FACR
• Email: ialmaghlouth@ksu.edu.sa
• Phone: 966544282266

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NTR-1011 for SLE and RA: initial safety testing in adults

  This study tests whether NTR-1011 is safe and tolerable in healthy adults and adults with SLE or RA, to see how the body handles the drug and whether there are early signs of benefit when added to standard care.

  Recruiting at 7 sites Phase 1 Neutrolis · Apple Valley, California and 6 other locations · NCT07237659

• Evaluating CTX112 for treating refractory autoimmune diseases in adults

  This study is testing a new CAR T cell treatment called CTX112 to see if it can help adults with tough autoimmune diseases like lupus and scleroderma feel better.

  Recruiting at 16 sites Phase 1 CRISPR Therapeutics · La Jolla, California and 16 other locations · NCT06925542

• Using CLN-978 to treat patients with systemic lupus erythematosus

  This study is testing a new treatment called CLN-978 to see if it can help people with moderate to severe lupus who haven't responded well to other treatments.

  Recruiting at 22 sites Phase 1 Cullinan Therapeutics Inc. · Avondale, Arizona and 23 other locations · NCT06613360

• Targeted CAR-T therapy for autoimmune diseases

  This study is testing a new type of CAR-T therapy to see if it can help people with active autoimmune diseases feel better and manage their symptoms.

  Recruiting Early Phase 1 Nanjing Bioheng Biotech Co., Ltd. · Bengbu, Anhui · NCT06548607

• Long-Term Extension of enpatoran for cutaneous lupus symptoms

  This extension study tests whether continuing enpatoran is safe and helpful for people with skin lupus who completed previous trials, for up to about two years.

  Recruiting Phase 3 EMD Serono · Troy, Michigan · NCT07840287

• Targeting B cells and plasma cells in lupus with a dual-action antibody

  A new injectable therapy (F182112) will be tested in adults with systemic lupus erythematosus to see if it can help by hitting both CD3 on immune cells and BCMA on B cells and plasma cells.

  Recruiting Phase 1 Shandong New Time Pharmaceutical Co., LTD · Shanghai · NCT07829614

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.